A Sequential Safety and Biomarker Study of BRAF-MEK Inhibition on the Immune Response in the Context of Combined CTLA-4 Blockade and PD-1 Blockade for BRAF Mutant Melanoma

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 11 Mar 2022

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Dabrafenib (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Trametinib (Primary)
Indications Malignant melanoma
Focus Adverse reactions; Biomarker

09 Mar 2022 Status changed from active, no longer recruiting to discontinued.
09 Mar 2022 Status changed from active, no longer recruiting to discontinued.
01 Jul 2020 Planned primary completion date changed from 1 Jun 2020 to 31 Dec 2020.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com